Studies show SIRT6 represses aerobic glycolysis in cancer cells and SIRT6 deficiency contributes to tumor formation even without any oncogene activation [153], indicating the glucose metabolic reprogramming is not a mere consequence of tumorigenesis but also one of its main drivers. Here, SIRT6 is linked to cancer.